Scarica l'app Stockscreener
2.86
0.00%
0.04
Precedente Chiudi:
$2.82
Aprire:
$2.81
Volume 24 ore:
104.18K
Relative Volume:
1.42
Capitalizzazione di mercato:
$42.34M
Reddito:
$486.00K
Utile/perdita netta:
$-28.43M
Rapporto P/E:
-0.2591
EPS:
-11.04
Flusso di cassa netto:
$-26.75M
1 W Prestazione:
-0.70%
1M Prestazione:
+17.50%
6M Prestazione:
+4.44%
1 anno Prestazione:
-29.85%
Intervallo 1D:
$2.79
$2.95
Intervallo di 1 settimana:
$2.65
$2.95
Portata 52W:
$1.57
$4.09
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Nome
Vyne Therapeutics Inc
Settore
Industria
Telefono
800-775-7936
Indirizzo
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Confronta VYNE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| VYNE | 2.86 | 42.34M | 486.00K | -28.43M | -26.75M | -11.04 |
| VRTX | 450.21 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.87 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 599.22 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.97 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.47 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-06 | Ripresa | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Borsa (VYNE) Ultime notizie
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - MSN
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential - Yahoo Finance
VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright - Defense World
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024 - TipRanks
VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VYNE Therapeutics Reports Strong Pipeline Progress, $70.2M Cash Position Despite Q3 Loss | VYNE Stock News - StockTitan
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World
(VYX) Long Term Investment Analysis - Stock Traders Daily
Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat
ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks
ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks
Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga
What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News
Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha
Wix.com (NASDAQ:WIX) Upgraded by Piper Sandler to "Overweight" - MarketBeat
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Xylem Inc. (NYSE:XYL) Shares Sold by Virtu Financial LLC - Defense World
A company insider recently bought 3,648 shares of NCR Voyix Corp [VYX]. Should You Buy? - Knox Daily
HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE reports positive early trial results for inflammation drug - Investing.com
VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks
VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
VYNE Therapeutics to Participate in September Investor Conferences - StockTitan
VYNE Therapeutics sees cash runway through end of 2025 - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World
VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace
Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way? - Simply Wall St
VYNE Therapeutics secures UK patent for inflammation drug - Investing.com
Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance
VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia
VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St
VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World
Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan
Vyne Therapeutics Inc Azioni (VYNE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):